...
首页> 外文期刊>Artificial Organs >Single-Center Experience With Extracorporeal Life Support in 103 Nonpostcardiotomy Patients
【24h】

Single-Center Experience With Extracorporeal Life Support in 103 Nonpostcardiotomy Patients

机译:103名非心脏切开术后患者的单中心经验与体外生命支持

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Extracorporeal membrane oxygenation (ECMO) has been successfully used to support patients with cardiac arrest failing to respond to conventional cardiopulmonary resuscitation (CPR). Preimplant factors being indicative for success are unknown up to now. The study describes single center experience with special focus on differences between survivors and nonsurvivors. Between 2002 and 2009, 103 patients were supported within the scope of CPR by means of ECMO. Besides primary diagnosis, duration, and outcome, pH, lactate, mean arterial pressure, aspartate aminotransferase, bilirubin, catecholamine dosage, and oxygenation ratio before ECMO, after 2h, 1 day, and at explantation were analyzed. One hundred three patients (51.2±16 years, 35 women, 68 men) were analyzed. Primary cardiac failure led to CPR in 54%. Duration of support was 4.8±0.6 days. Twenty-nine (28.1%) patients survived to hospital discharge. On ECMO support, pH, lactate, and mean arterial pressure improved significantly. Catecholamine dosage was significantly reduced after ECMO implantation. Demographic data and primary diagnosis revealed no significant influence on outcome. pH, lactate, creatinine, and bilirubin differed significantly between survivors and nonsurvivors in the course of ECMO support. ECMO support during CPR reliably improves the circulatory and respiratory situation. Considering observed survival critical patient selection is mandatory. Although there are several significant differences between surviving patients and patients with fatal outcome, patient selection turns out to be difficult as clinically relevant factors show only limited predictive value. Future research should focus on better defining a population that may be best of all suited for the use of ECMO support in CPR. Artificial Organs
机译:体外膜氧合(ECMO)已成功用于支持对常规心肺复苏(CPR)无效的心脏骤停患者。迄今为止,尚无法确定植入前成功的因素。该研究描述了单中心经验,并特别关注幸存者与非幸存者之间的差异。在2002年至2009年之间,通过ECMO在CPR范围内支持了103名患者。除了初步诊断,病程和预后外,还分析了ECMO之前,2h,1天和移植后的pH,乳酸,平均动脉压,天冬氨酸转氨酶,胆红素,儿茶酚胺剂量和氧合率。分析了103例患者(51.2±16岁,女性35例,男性68例)。原发性心力衰竭导致CPR的发生率为54%。支持时间为4.8±0.6天。 29名患者(28.1%)存活到医院出院。在ECMO支持下,pH,乳酸和平均动脉压显着改善。 ECMO植入后,儿茶酚胺剂量明显减少。人口统计学数据和初步诊断显示对结局无重大影响。在ECMO支持过程中,幸存者和非幸存者之间的pH,乳酸,肌酐和胆红素差异显着。心肺复苏期间的ECMO支持可靠地改善了循环和呼吸状况。考虑观察生存至关重要的患者选择是强制性的。尽管幸存的患者和具有致命结果的患者之间存在若干显着差异,但由于临床相关因素仅显示出有限的预测价值,因此患者选择仍然非常困难。未来的研究应集中在更好地定义最适合在CPR中使用ECMO支持的人群。人工器官

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号